USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.